CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)

Lancet

Volumn 351, Issue 9104, 1998, Pages 723-724

  Kaufmann, Daniel ^b   Pantaleo, Giuseppe ^b   Sudre, Philippe ^b   Telenti, Amalio ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Swiss HIV Cohort Study Data Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ARTICLE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TIME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 0032492398     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24010-4     Document Type: Article

References (4)

1. 1 Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: a prospective multicentre study. BMJ 1997; 315: 1194-99.
2. 2 Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 1: F113-16.
3. 3 Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
4. 4 Brun-Vezinet F, Boucher C, Loceday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997; 350: 90-90.